Sun Pharma Agrees to $85 Million in Settlements Over Price-Fixing Allegations

Two U.S. subsidiaries of Indian generics company Sun Pharmaceutical Industries have reached settlements totaling $85 million with plaintiffs in the companies’ drug-pricing antitrust litigation, said Sun in a statement.

The settlements come after a multidistrict litigation over alleged price fixing.

“Taro Pharmaceuticals USA and Sun Pharmaceutical Industries have signed settlement agreements with the Direct Purchaser Plaintiffs in the in re Generic Pharmaceuticals Pricing Antitrust Litigation that has been taking place in the Eastern District of Pennsylvania … for some time," Sun Pharma said in a filing with the Securities and Exchange Commission.

From 2013 to 2015, according to the U.S. Department of Justice, Taro Pharmaceuticals USA, Sandoz and Apotex are alleged to have conspired to set prices on a number of popular unnamed generic drugs. The companies are alleged to have paid each other — and other unnamed companies — to manipulate price, supply and customer allocations between 2013 and 2015.